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Colitis associated cancer (CAC) is the colorectal cancer (CRC) subtype that is associated with bowel disease such as ulcerative colitis
(UC). The data on role of NF-𝜅B signaling in development and progression of CAC were derived from preclinical studies, whereas
data from human are rare. The aim of this work was to study the contribution of NF-𝜅B pathway during UC and CAC, as well as
the immunomodulatory effect of all-trans retinoic acid (AtRA). We analyzed the expression of NOS2, TNF-𝛼, TLR4, and NF-𝜅B,
in colonic mucosa. We also studied NO/TNF-𝛼modulation by LPS in colonic mucosa pretreated with AtRA. Amarked increase in
TLR4, NF-𝜅B, TNF-𝛼, and NOS2 expression was reported in colonic mucosa.The relationship between LPS/TLR4 and TNF-𝛼/NO
production, as well as the role of NF-𝜅B signaling, was confirmed by ex vivo experiments and the role of LPS/TLR4 in NOS2/TNF-
𝛼 induction through NF-𝜅B pathway was suggested. AtRA downregulates NOS2 and TNF-𝛼 expression. Collectively, our study
indicates that AtRA modulates in situ LPS/TLR4/NF-𝜅B signaling pathway targeting NOS2 and TNF-𝛼 expression. Therefore, we
suggest that AtRA has a potential value in new strategies to improve the current therapy, as well as in the clinical prevention of CAC
development and progression.
1. Introduction
Colorectal cancer (CRC) is one of the most common lethal
cancers worldwide [1]. There are two major types of CRC,
sporadic colorectal carcinoma (SCC) and colitis associated
cancer (CAC) [2]. Factors that may increase the risk of
colorectal cancer have been extensively studied [3, 4]. Phys-
ical inactivity, obesity, smoking, and dietary patterns such
as high red and processed meat consumption as well as
moderate-to-heavy alcohol use also increase the risk for CRC
[4–6]. Several reports have shown that chronic inflammation
predisposes individuals to various types of cancer [3, 7, 8].
The risk of colorectal cancer is increased in patients with
inflammatory bowel disease, particularly in long-standing
and extensive ulcerative colitis (UC) [8]. Then, colitis associ-
ated cancer (CAC) is the CRC subtype that is associated with
bowel disease (Crohn’s disease (CD) and ulcerative colitis
(UC)) [9]. Both diseases are characterized by the immune
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dysregulation in the intestine, involving a wide range of
molecules leading to a chronically inflamed environment
[10–12].
Althoughmany reports have documented the critical link
between inflammation and development of colon cancer, our
knowledge of the underlying mechanisms remains incom-
plete. Different TLR ligands have been implicated in various
experimental tumor models and are known to play different
roles. While some TLRs contribute to antitumor responses,
others conversely promote tumor growth and facilitate the
evasion of immune surveillance [13]. TLR4 signaling plays
a crucial role in the generation of innate response but also
serves to activate the adaptive immune system in response
to cancer [13, 14]. Activation of TLR4 by Gram-negative
lipopolysaccharide (LPS) leads to the NF-𝜅B activation in
the intestinal mucosa [15] and induced the expression of
many proinflammatory molecules including cytokines and
adhesion molecules [16, 17]. Among these cytokines, tumor
necrosis factor-alpha (TNF-𝛼) can further enhance NF-
𝜅B activation in various cell types [18]. TNF-𝛼 is a mul-
tifunctional cytokine involved in apoptosis, cell survival,
inflammation, and immunity acting via two receptors (TNF
receptor p55 or TNF-Rp75) [19, 20].
Proinflammatory mediators and cytokines such as nitric
oxide (NO) and TNF-𝛼 play important roles in regulating
inflammatory response. Generation and secretion of a high
NO concentration by infiltrating cells and resident activated
macrophagesmay lead to perpetuation of local tissue damage
[21, 22]. The inducible NOS (iNOS) is expressed following
stimulation with lipopolysaccharide and/or inflammatory
cytokines such as TNF-𝛼 [22–24]. The activation of iNOS
leads to prolonged production of NO in high, potentially
cytotoxic concentrations [25]. In our previous studies, we
reported that chronic UC is characterized by overexpression
of iNOS with high levels of NO generation by PBMC
and colonic mucosa stimulated with IFN-𝛾 or IL-17A and
correlates with histological damage [10, 11]. Thus iNOS
generatedNOmay give the cell a double hit by both damaging
the DNA and inhibiting its repair processes. This effect of
NO and its by-products may make NO one of the pivotal
mediators linking inflammation to carcinogenesis [25].These
observations suggest that iNOS may also play a fundamental
role in the enhancement of colon cancers risk in IBD patients,
as well as in promotion/progression of cancers arising within
a background of inflammation [26].However, the data on role
of TLR4/NF-𝜅B signaling in TNF-𝛼/iNOS induction in UC-
associated carcinogenesis are still not fully understood and
derived from preclinical studies, whereas data from human
CAC are rare.
Great progress has been made in the development of
chemotherapy, as well as targeted therapies for advanced
different forms of CRC. Meanwhile, many cases show that
tolerance develops to such treatments [27]. However, the
treatment of different forms of CCR included CAC requires
new strategies to improve the current therapy. It has been
reported that induction of NF-kB activation leads to the
resistance to chemotherapy [28].
Accumulative researches indicated that retinoids were
associated with the prevention and amelioration of numerous
chronic diseases and cancers [29–32]. Retinoids are currently
used as chemotherapies against cancers of epithelial origin
[33]. All-trans retinoic acid (AtRA) is an active metabolite
of retinoid and regulates a wide range of biologic processes
through the action of two families of nuclear retinoid recep-
tors, retinoid acid receptor (RAR) and retinoid X receptor
(RXR). Heterodimers composed of an RAR and an RXR bind
to specific RA response elements (RAREs) in target genes
[34, 35].
AtRA has been shown to exert immunomodulatory and
anti-inflammatory functions in various cell types [36–38]. In
our previous studies, we reported that AtRA inhibited theNO
production in proinflammatory cytokines stimulated periph-
eral blood mononuclear cells (PBMC) and monocytes from
IBD and Alzheimer disease patients [11, 39]. Furthermore,
retinoids are known to affect signaling pathways frequently
altered which result in the development and progression of
CRC [32]. In this sense, understanding the pathway involved
in cancer-related inflammation and targeting transcription
factors such as NF-𝜅B has attracted our attention. In this way,
we investigate the contribution of TLR4/NF-𝜅B pathway in
UC and CAC Algerian patients, as well as the effect of AtRA
on TNF-𝛼 and NOS2 expression.
2. Patients and Methods
2.1. Patients. Thirty-five Algerian patients with ulcerative
colitis, UC (14 men and 16 women; mean age 39.75 ±
9.23 years; range 22–53 years), and 9 patients with colitis
associated cancer, CAC (3 men and 6 women; mean age
55.88 ± 6.66 years; range 48–67 years), were enrolled in this
study. UC and CAC patients were diagnosed by standard
endoscopic and histological examination in the Department
of Gastroenterology, Maillot Hospital, Algiers, Algeria, Ser-
vice of Oncology, Public hospital Rouiba Algiers Algeria
and Anatomic Pathology service, Mustapha Pacha Algiers
Algeria.
The histopathological examination confirmed the diag-
nosis of UC active stage and cancer. Healthy controls (𝑛 =
16) were obtained from adult volunteer donors. Each patient
has given a written informal consent for the study required
by the ethic committee of the national agency of research
development in health (ATRSS) which supported our project.
2.2. Plasma Collection. Blood samples collected from healthy
donors and patients were centrifuged at 2,000 rpm for 10min
to obtain plasma. All plasma samples were stored at −45∘C
until TNF-𝛼 and nitric oxide (NO) determination.
2.3. Colonic Biopsies and Culture. Multiple colonic biopsies
were taken from patients who underwent colonoscopy in the
Department of Gastroenterology, Maillot Hospital (Algiers,
Algeria), Anatomic Pathology Service, Mustapha Pacha
(Algiers, Algeria), and Service of Oncology, Public Hospital
Rouiba, (Algiers, Algeria). Our study included biopsies from
inflamed mucosa of patients with UC in active stage (𝑛 =
12) and with CAC (𝑛 = 6). Biopsies from normal mucosa
(𝑛 = 6) were also used as negative controls. Colonic biopsies
were immediately placed in the transport medium Hanks’
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Table 1: Summary of primers sequences used for qRT-PCR.
Gene 5󸀠 primer (5󸀠-3󸀠) 3󸀠 primer (5󸀠-3󸀠)
TNF-𝛼 ATCTTCTCGAACCCCGAGTGA GGAGCTGCCCCTCAGCTT
TNFRp55 GCTTCAGAAAACCACCTCAGACA CCGGTCCACTGTGCAA
TNFRp75 CAACACGACTTCATCCACGG GACGTGCAGACTGCATCCAT
TLR4 CCCGACAACCTCCCCTTCT TGCCCCATCTTCAATTGTCTG
NOS2 TGACCCTGAGCTCTTCGAAATC AGGGCGTACCACTTTAGCTCC
TNF-𝛼: tumor necrosis factor-alpha; TNFRp55/p75: tumor necrosis factor receptor; TLR4: toll like receptor-4; NOS2 (iNOS): NO synthase 2; NO: nitric oxide.
balanced salts solution, pH 7.4, supplemented with antibi-
otics. Cultures of colonic mucosa were pretreated with all-
trans retinoic acid (AtRA) at 10−7M for 6 h and stimulated
with lipopolysaccharide (LPS; 10 𝜇g/mL). To confirm the
engagement of NF-kB signaling pathway on TNF-𝛼 and
NO production, colonic biopsies were stimulated with LPS
(10 𝜇g/mL) and SN50, an inhibitor peptide of NF-𝜅B, AP-
1, and STAT pathways (50 𝜇M/mL). The cultures were incu-
bated at 37∘C in an atmosphere of 5% CO2 up to 24 hours.
Supernatants were then collected for NO (nitrite) and TNF-
𝛼 measurement. The estimation of total protein per well
was performed using Bradford method and nitrite or TNF-
𝛼 contents of each well were expressed as 𝜇M/mg or pg/mL
of total protein, respectively [40].
2.4. Enzyme-Linked Immunosorbent Assay for Human TNF-
𝛼. Plasma TNF-𝛼 levels were determined by using enzyme-
linked immunosorbent assay (ELISA) kit according to the
manufacturer’s instructions (Invitrogen-Life Technologies,
USA). The absorbance was read on an ELISA reader at
450 nm (LABSYSTEM). These assays detected only human
cytokines. The results are expressed as picograms per
milliliter relating to a standardized dose curve of the relevant
recombinant TNF-𝛼.
2.5. Nitric Oxide (NO) Production. The stable nitrite (NO−2)
concentration, being the end product of NO oxidation, was
determined by the method described by Touil-Boukoffa and
others (1998). Briefly, nitrite (NO−2) was quantified by spec-
trophotometry (at 543 nm) in samples (plasma, supernatants
of colonic mucosa culture) after reaction with Griess reagent.
The NO−2 concentration was determined by extrapolation
from a NaNO2 standard curve and expressed as 𝜇M/mL
[41].
2.6. RNA Extraction and Real-Time Quantitative PCR. Total
RNA was extracted from colonic mucosa using a QIAGEN
RNeasy kit (QIAGEN).After reverse transcription into cDNA
with a Reverse Transcription Kit (Bio-Rad), qPCR was then
performed on MyiQ single color RT-PCR detection system
with SYBR Green Super Mix (Bio-Rad) and gene-specific
primers were summarized in Table 1. We normalized gene
expression amount to 𝛽-actin and GAPDH housekeeping
gene and represented data as fold differences by the 2−ΔΔCt
method,whereΔCt=Ct target gene –CtMGandΔΔCt=ΔCt
patients − ΔCt control. Fold changes were calculated using
the comparative Ct method.
2.7. Histological Analysis. Multiple colonic biopsies were
taken from patients (active UC, 𝑛 = 10; CAC, 𝑛 =
9) and were fixed for 24 hours in buffered formaldehyde
solution (10% in PBS) at room temperature. The biopsies
were dehydrated by graded ethanol and embedded in paraffin
(solidification point 60–62∘C). Tissue sections (thickness
3 𝜇m) were deparaffinized with toluene, stained with hema-
toxylin and eosin (H&E). Digital images were captured with
digital camera at ×400 resolution. Each colonic segment was
evaluated based on the Geboes histology score. Scores can
range from 0 to 5.4, with higher scores indicatingmore severe
histological inflammation.
2.8. Immunohistochemistry. Sections (3 𝜇m) were cut from
paraffin embedded tissues and mounted on positively
charged super frost slides. Tissues were deparaffinized and
rehydrated through graded alcohols. All sections were incu-
bated in 3% hydrogen peroxide (10min) to blockade endoge-
nous peroxidase activity. Nonspecific binding was blocked
by incubation (2 hours) in PBS containing 5% skim milk.
The sections were subsequently incubated overnight at 4∘C in
monoclonalmouse anti-TLR4 (Invitrogen-Life Technologies,
USA) (diluted 1 : 100 in phosphate buffered saline (PBS) con-
taining 5% skimmilk). Binding of the primary anti-TLR4was
detected with biotinylated rabbit anti-mouse immunoglobu-
lin horse radish peroxidase- (HRP-) conjugated streptavidin
(1 : 500). Immunoreactive complexes were detected using
DAB system (Invitrogen-Life Technologies, USA). Slides
were counterstained briefly in hematoxylin (Sigma Aldrich)
and mounted in Eukit (Sigma Aldrich). Slides were observed
using a standard microscope (Zeiss) and pictures were taken
using a digital camera at ×100 resolution. The intensity
of staining of each section was evaluated subjectively by
three separate observers in 4 fields nonoverlapping using
the following designations: 0–10% of cells stained, score 0;
11–25% of cells stained, score 1; 26–50% of cells stained,
score 2; 51–100% of cells stained, score 3. Those scoring 0-1
were considered to be negative, and those scoring 2-3 were
considered to be positive.
2.9. Western Blot. The biopsies were lysed with phosphate
buffered containing 1% Triton X-100 and 1% protease
inhibitor mixture (Sigma Aldrich). Protein concentrations
were determined using a Bio-Rad Protein Assay (Bio-Rad,
Marnes la Coquette, France) according to manufacturer’s
instructions. SDS-PAGE was performed according to the
Laemmeli procedure using gradient precasts gels (4–12%
gradient, Bis-Tris) (Invitrogen). Proteins were transferred on
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to PVDF membrane (Millipore, Molsheim, France) and
probed with primary Ab (anti-TLR4, 1/1000) (Invitrogen-
Life Technologies, USA) and the rabbit anti-𝛽-actin as inner
control. The membranes were incubated with peroxidase-
conjugated secondary antibodies (anti-rabbit, 1 : 10000) (GE
Healthcare, Wauwatosa, WI, USA) and washed again with
blocking buffer. Specific protein signals were visualized
using Western Lightning H Plus, ECL, Enhanced Chemi-
luminescence Substrate kit (PerkinElmer, Boston, MA,
USA).
2.10. Immunohistofluorescence. Colonic mucosa sections
(3 𝜇m) were saturated by incubation (2 hours) in PBS
containing 5% skim milk and then permeabilised with 0.1%
Triton X-100. A rabbit IgG1 monoclonal antibody (diluted
1/100), a mouse IgG1 monoclonal antibody (diluted 1/100),
a rabbit IgG1 monoclonal antibody (diluted 1/100), and a
rabbit IgG1 monoclonal antibody (diluted 1/50) were used
as primary antibody for NF-𝜅B, Ikk, NOS2, and TNF-𝛼
detection, respectively. Fluorescein isothiocyanate- (FITC-)
conjugated IgG was used as secondary antibody. Slides were
covered with Kaiser’s glycerin-PBS and observed using a
standard microscope (Zeiss) and pictures were taken using
a digital camera at ×100 resolution. The intensity of staining
of each section was evaluated subjectively by three separate
observers in 4 fields nonoverlapping using the following
designations: 0–10% of cells stained, score 0; 11–25% of cells
stained, score 1; 26–50% of cells stained, score 2; 51–100%
of cells stained, score 3. Those scoring 0-1 were considered
to be negative, and those scoring 2-3 were considered to be
positive.
2.11. Statistical Analysis. All results were expressed as mean
± standard deviation. Data analysis was performed using
Minitab 16. Student’s 𝑡-test was used for comparison between
different groups. Differences were considered to be statisti-
cally significant at 𝑃 < 0.05.
3. Results
3.1. The Relationship between Nitric Oxide and TNF-𝛼 Levels
in Plasma of UC and CAC Patients. In order to assess the
involvement of TNF-𝛼 and NOS2 during UC and CAC,
at first, we analyzed the NO and TNF-𝛼 production in
vivo. Analysis of nitric oxide (NO) and circulating TNF-
𝛼 production by Griess method and ELISA, respectively,
revealed that NO andTNF-𝛼 levels are increased in all groups
of patients in comparison to the healthy controls (𝑃 < 0.001)
(Table 2). Interestingly, TNF-𝛼 levels are higher in sera of
patients with CAC than in sera of patients with active UC
(374.7 ± 16.31 pg/mL versus 291.48± 19.03 pg/mL) (Table 2).
In contrast, no statistically significant difference in NO levels
was observed between active UC and CAC patients (45.67 ±
6.14 𝜇M versus 43.91 ± 7.28 𝜇M) (𝑃 > 0.05) (Table 2).
As shown in Figure 1(a), there is a significant positive
correlation between NO levels and TNF-𝛼 levels in plasma
of active UC (𝑅2 = 0.78; 𝑃 < 0.01). A similar observation
was observed in CAC patients, who presented linear positive
Table 2: Sera TNF-𝛼 and NO concentrations in patients with
ulcerative colitis and colitis associated cancer.
[TNF-𝛼] (pg/ml) NO (𝜇M)
UC (𝑛 = 35) 291,48 ± 19,03 (𝑃 < 0,001) 45,67 ± 6,14 (𝑃 < 0,001)
CAC (𝑛 = 9) 374,7 ± 16,42 (𝑃 < 0,001) 43,91 ± 7,28 (𝑃 < 0,001)
HD (𝑛 = 18) 18,54 ± 5,31 21,32 ± 5,16
Values represent the mean ± standard deviation.
Significance compared with healthy donors: 𝑃 < 0.001.
TNF-𝛼: significant difference between the two groups of patients (active
UC/CAC) is indicated (𝑃 < 0.05).
NO: no significant difference between the two groups of patients (UC/CAC)
is indicated (𝑃 > 0.05).
HD, healthy donors; UC, ulcerative colitis; CAC, colitis associated cancer.
correlation between NO levels and TNF-𝛼 (𝑅2 = 0.92; 𝑃 <
0.01) (Figure 1(b)).
3.2. TNF-𝛼 andNOS2Expression inColonicMucosa ofUCand
CACPatients: CorrelationwithHistological Damage. Consid-
ering the high levels of circulatingNO and TNF-𝛼 assessed in
vivo, we decided to determine the possibility of upregulation
of NOS2 and TNF-𝛼/TNFR expression in inflamed colonic
mucosa of UC and CAC patients. Therefore, we analyzed the
expression of messenger-RNAs (mRNAs) encoding TNF-𝛼
and TNF receptors (TNFRp55 and TNFRp75) in inflamed
colonic mucosa from UC and CAC patients. The NOS2
(iNOS) mRNA expression was also analyzed by QPCR in
these patients.
As shown in Figure 2, analysis of TNF-𝛼, TNF receptors,
and NOS2 transcripts reveals that messenger-RNA transcript
levels of the indicated genes are elevated in inflamed colonic
mucosa from all groups of patients as compared with normal
colonic mucosa. Moreover, TNF-𝛼 mRNA expressions are
higher in colonic mucosa of patient’s with CAC than in
colonic mucosa of patients with active UC (𝑃 < 0.01). A
similar observation was noted in CAC patients, who pre-
sented significantly higher TNFRp75mRNA levels compared
with active UC patients (∼2-fold 𝑃 < 0.01). In contrast,
no statistically significant difference in TNFRp55 and NOS2
mRNA expression was detected between active UC and CAC
patients (𝑃 > 0.05) (Figure 2).
In addition, immunofluorescence analysis showed that
TNF-𝛼 protein expression was upregulated in inflamed
colonic mucosa of all cohorts of patients in comparison with
the controls (Figure 3). We also noted that NOS2 expression
was upregulated in colonic mucosa of UC and CAC patients
compared with the controls (Figure 3).
The histological study indicated a profound colonic
inflammation (higher score) characterized by crypt destruc-
tion. Inflammatory cells infiltration into mucosa in UC
patients (Figure 4(b)) was also noticed compared to colonic
mucosa control showing normal structure (Figure 4(a)). A
similar observation was noticed in colonic mucosa of CAC
patients (Figure 4(c)).
Considering the overexpression of iNOS and TNF-𝛼
in inflamed colonic mucosa of UC and CAC patients, we
also decided to evaluate the percentage of mixed leukocytes
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Figure 1: Correlation between the serum NO levels and the serum TNF-𝛼 levels in Algerian patients with (a) active UC and (b) CAC. (a)
There is a significant correlation between NO levels and TNF-𝛼 levels in patients with active UC (𝑅2 = 0.78). (b) There is a significant
correlation between the NO levels and TNF-𝛼 (𝑅2 = 0.92) levels in patients with CAC (TNF-𝛼, tumor necrosis factor-alpha; NO, nitric oxide;
UC, ulcerative colitis; CAC, colitis associated cancer).
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Figure 2: Messenger-RNA (mRNA) transcripts of TNF-𝛼, TNFR
(p55, p75), and iNOS were quantitated in colonic mucosa of
patients with UC and CAC. Expression was normalized against
𝛽-actin and GAPDH housekeeping gene, and relative expression
was represented data as fold differences by the 2−ΔΔCt method,
where ΔCt = Ct target gene − Ct MG and ΔΔCt = ΔCt inflamed
colonic mucosa − ΔCt normal colonic mucosa. Fold changes were
calculated using the comparative Ct method. Data represent mean
± standard deviation. Significant difference between the two groups
of patients (UC/CAC) is indicated (∗𝑃 < 0.05). ns, no significant
difference, 𝑃 > 0.05 (UC, ulcerative colitis, 𝑛 = 12; CAC, colitis
associated cancer, 𝑛 = 5; C, control, 𝑛 = 5).
(inflammatory cell infiltrate) in areas with higher or low
expression of iNOS and TNF-𝛼.
Interestingly, the percentage ofmixed leukocytes is higher
in areas of iNOS overexpression than in areas with low iNOS
expression in UC and CAC patients (Figure 5(a); UC: 75%
versus 25%; CAC: 61% versus 18%) (𝑃 < 0.01). A similar
observation was noted in areas with higher expression of
TNF-𝛼 when compared with areas of low TNF-𝛼 expression
(Figure 5(b); UC: 81% versus 19%; CAC: 55% versus 15%)
(𝑃 < 0.01). Our finding showed that the overexpression of
iNOS (NOS2) and TNF-𝛼 in inflamed colonic mucosa was
associated with histological damage.
3.3. LPS/Toll Like Receptor-4 (TLR4) Signaling Induced Nitric
Oxide and TNF-𝛼 Production by Colonic Mucosa through NF-
𝜅B Pathway. Several studies have demonstrated that TLR4
expression is known to be low in the normal colon but
increased in inflammatory bowel disease (ulcerative colitis
and Crohn’s disease) [16, 26, 28]. We hypothesized that TLR4
expression is upregulated in colitis associated tumors and
plays a pivotal role to induce iNOS and TNF-𝛼 expression
through NF-𝜅B pathway.
Colon specimens from patients with UC or CAC were
examined for TLR4 mRNA expression by Q-PCR. We also
evaluated TLR4 protein expression in inflamed colonic
mucosa by Western blot analysis and immunohistochemical
staining. In addition, NF-𝜅B and iKK protein expression was
assessed in inflamed colonic mucosa from the same patients
by immunofluorescent staining.
Transcriptomic analysis of TLR4 showed that levels of
mRNA transcripts of the indicated gene are elevated in
inflamed colonicmucosa of all cohorts of patients in compar-
ison with the controls (𝑃 < 0.001), especially in CAC patients
(𝑃 < 0.01) (Figure 6).
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Figure 3: TNF-𝛼 and NOS2 expression in inflamed colonic mucosa of active UC and CAC patients detected by immunofluorescent staining
(IF). TNF-𝛼 and NOS2 expression was upregulated in inflamed colonic mucosa (higher inflammation score) of active UC and CAC patients
compared with control. Immunofluorescence staining of NOS2 (score 3) and TNF-𝛼 (score 3) was more intense in inflamed colonic mucosa
of UC patients compared with control (score 0). High score and intensity of NOS2 (score 3) and TNF-𝛼 (score 3) were also evaluated in
colonic mucosa of CAC patients (UC, ulcerative colitis, 𝑛 = 5; CAC, colitis associated cancer, 𝑛 = 3; C, control, 𝑛 = 4).
(a) (b) (c)
Figure 4: Representative photomicrographs of H&E-stained (a) colonic mucosa from control, (b) active UC patients (severe inflammation;
higher score 5.4), and (c) CAC patients (severe inflammation; higher score 5.4). Arrows show cellular infiltrate and crypt destruction (UC,
ulcerative colitis, 𝑛 = 10; CAC, colitis associated cancer, 𝑛 = 9; C, control, 𝑛 = 5).
In our current study, we also observed with interest that
TLR4 protein expression was upregulated in colonic mucosa
of patients compared with the controls, especially in patients
with CAC (Figures 7 and 8).
Immunofluorescent staining analysis indicated that NF-
𝜅B and iKK protein expression is highly increased in
colonic mucosa of UC patients in comparison with controls
(Figure 9). A similar result was reported in CAC patients,
who presented higher NF-𝜅B/iKK expression compared with
controls (Figure 9).
To further confirm the relationship between LPS/TLR4
and TNF𝛼/NOS2 induction, as well as the role of NF-𝜅B
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Figure 5: Percentage of mixed leukocytes in areas with high or low
expression of iNOS and TNF-𝛼. Mixed leukocytes (inflammatory
cell infiltrate) were counted in 4 wells nonoverlapping in areas of
iNOS/TNF-𝛼 overexpression and areas with low expression. High
density of mixed leukocytes was observed in areas of iNOS and
TNF-𝛼 overexpression as compared with areas of low iNOS/TNF-𝛼
expression in colonic mucosa of UC and CAC patients (∗∗𝑃 < 0.01).
signaling in ulcerative colitis and colitis associated tumori-
genesis, we used ex vivo experiments. Colonic mucosa of UC
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Figure 6: mRNA transcripts of TLR4 were quantitated in colonic
mucosa of UC and CAC patients. Expression was normalized
against 𝛽-actin, HPRT, and GAPDH housekeeping gene, and rel-
ative expression was represented data as fold differences by the
2−ΔΔCt method, where ΔCt = Ct target gene − Ct MG and ΔΔCt
= ΔCt inflamed colonic mucosa − ΔCt normal colonic mucosa.
Fold changes were calculated using the comparative Ct method.
Data represent mean ± standard deviation. Significant difference
between patients (UC/CAC) and controls is indicated (𝑃 < 0.001).
Significant difference between 2 groups of patients (UC/CAC) is
indicated (∗∗𝑃 < 0.01) (UC, ulcerative colitis, 𝑛 = 12; CAC, colitis
associated cancer, 𝑛 = 5; C, control, 𝑛 = 5).
and CAC patients was stimulated with LPS (10 𝜇g/mL) in the
absence or presence of SN50 (50 𝜇M/mL). NO and TNF-𝛼
production was analyzed after 24 hours of incubation.
As shown in Figure 10, stimulation with LPS increases
NO andTNF-𝛼 production by inflamed colonicmucosa from
patients with activeUC comparedwith unstimulated biopsies
(𝑃 < 0.01). These findings were also observed in the culture
with colonicmucosa of CAC patients (𝑃 < 0.001) (Figure 10).
Our study showed that SN50 (50𝜇M/mL) inhibited LPS
induction of NO and TNF-𝛼 production in inflamed colonic
mucosa cultures in all groups of patients (Figure 10). The
SN50 in colonic mucosa culture stimulated with LPS from
CAC patients causes a significant decrease of the amount
of NO (−1.24-fold, 𝑃 < 0.01) and TNF-𝛼 (−1.18-fold, 𝑃 <
0.05) compared with colonic mucosa stimulated with LPS
alone (Figure 10). The same profile was observed for colonic
mucosa treated with SN50 from the patients with UC (𝑃 <
0.05) (Figure 10).
3.4. All-Trans Retinoic Acid (AtRA)Modulates a TNF-𝛼Major
InflammationCytokine andNOSynthase 2 (iNOS) in Inflamed
Colonic Mucosa of UC and CAC Patients. Having demon-
strated the link between TLR4/NF-𝜅B and TNF-𝛼/NOS2
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Figure 7: The expressions of TLR4 in colonic mucosa of UC and CAC patients detected by Western blot. (a) Representative Western blot
analysis of total biopsies homogenate from colonic mucosa of active UC and CAC patients. A TLR4 specific polyclonal antibody recognized
a protein whose molecular weight was approximately 95 kDa. (b) The relative intensity of TLR4 (C: control, colonic mucosa, 𝑛 = 3; UC:
ulcerative colitis, 𝑛 = 5; CAC: colitis associated cancer, 𝑛 = 3).
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Figure 8: Immunohistochemical expression of TLR4. Control colonic mucosa shows a low expression of TLR4 (score 0). This expression
was profoundly increased in colonic mucosa of patients UC (score 3) and CAC (score 3) (UC: ulcerative colitis, 𝑛 = 6; CAC: colitis associated
cancer, 𝑛 = 4; C: control, normal mucosa, 𝑛 = 3).
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Figure 9: The expression of NF-𝜅B (P50) and ikk𝛾 in colonic mucosa of UC and CAC patients detected by IF. NF-𝜅B (score 3) and ikk𝛾
(score 3) expression was upregulated in colonic mucosa of active UC and CAC patients compared with control (score 0) (UC: ulcerative
colitis, 𝑛 = 6; CAC: colitis associated cancer, 𝑛 = 4; C: control, normal mucosa, 𝑛 = 3).
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Figure 10: Role of NF-𝜅B signaling on nitric oxide (a) and TNF-𝛼 (b) production by colonic mucosa stimulated with LPS (10 𝜇g/ml) in UC
andCAC patients. Values representmean ± standard deviation. Significance compared with control: ∗∗∗𝑃 < 0.001, ∗∗𝑃 < 0.01, and ∗𝑃 < 0.05;
ns: no significant difference (UC: ulcerative colitis; CAC: colitis associated cancer; C: control, normal mucosa).
induction in colorectal tumors, we focused our attention to
elucidate the immunomodulatory effect of all-trans retinoic
acid in NOS2 and TNF-𝛼 expression in inflamed colonic
mucosa cultures. We used RT-PCR to study NOS2 and TNF-
𝛼 mRNAs in colonic mucosa pretreated with AtRA (10−7M)
and stimulated with LPS. We also evaluated NO and TNF-𝛼
production by these colonic mucosae using Griess method
and ELISA, respectively. Finally, we examined the ability
of AtRA to modulate NOS2 protein expression in colonic
mucosa from UC and CAC patients in response to LPS.
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Figure 11: Effect of LPS (10𝜇g/ml) in the presence or absence of AtRA (10−7M) on NO2 (a) and TNF-𝛼 (b) mRNA expression in colonic
mucosa of patients with active UC and CAC. Values represent mean ± standard deviation. Significance compared with control: ∗𝑃 < 0.05,
∗∗
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Figure 12: Effect of LPS (10 𝜇g/ml) in the presence or absence of AtRA (10−7M) on NO (a) and TNF-𝛼 (b) production by colonic mucosa of
patients with active UC and CAC. Values represent mean ± standard deviation. Significance compared with control: ∗𝑃 < 0.05, ∗∗𝑃 < 0.01,
and ∗∗∗𝑃 < 0.001. ns, no significant difference, 𝑃 > 0.05 (UC: ulcerative colitis; CAC: colitis associated cancer; C: control, normal mucosa).
Our study showed that AtRA inhibited LPS induction
of NOS2 and TNF-𝛼 mRNA expression in inflamed colonic
mucosa cultures of all patients (Figure 11). Moreover, the
pretreatment of colonic mucosa of CAC patients with AtRA
decreased significantly NOS2 (−1.50-fold, 𝑃 < 0.05) and
TNF-𝛼 (−1.25-fold, 𝑃 < 0.05) mRNA expression compared
with colonic mucosa stimulated with LPS alone (Figures
11(a) and 11(b), resp.). The same profile was reported for
colonic mucosa treated with AtRA from the patients with
UC (𝑃 < 0.01) (Figures 11(a) and 11(b)). Figure 12 illustrates
the significant downregulation of NO and TNF-𝛼 produc-
tion by UC and CAC patients’ colonic mucosa pretreated
with AtRA in response to LPS compared with the controls
(𝑃 < 0.001).
Finally, we have investigated whether AtRA inhibits NO
production directly by modulating iNOS expression. Inter-
estingly, we report in our work that the pretreatment with
AtRA decreased significantly NOS2 expression in colonic
mucosa stimulated with LPS in all groups of patients
(Figure 13). Indeed, the immunofluorescence analysis showed
that NOS2 expression was downregulated in colonic mucosa
cultures pretreated with AtRA in the presence of LPS in all
groups of patients (UC and CAC) compared with controls
(Figure 13).
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Figure 13: Effect of LPS (10 𝜇g/ml) in the presence or absence of AtRA (10−7M) on NOS2 (iNOS) expression in inflamed colonic mucosa of
patients with active UC and CAC. AtRA reduced NOS2 expression in colonic mucosa (UC: ulcerative colitis; CAC: colitis associated cancer).
4. Discussion
It is possible that overproduction of inflammatorymediators,
including proinflammatory cytokines, during IBD may facil-
itate the development and progression of colorectal cancer
[8, 42–44]. It was reported that several key genes in the
inflammatory process such as NF-𝜅B provide a mechanistic
link between inflammation and cancer [45–48]. Activation of
TLRs and TNFR leads to NF-𝜅B activation and induced the
expression of many proinflammatory molecules including
NO synthase 2 (iNOS) [49, 50]. A growing number of studies
have reported the key role of TLR4/NF-𝜅B/TNF-𝛼 signaling
to promote tumor growth in experimental models of colitis
associated cancer [44, 51–53], whereas data fromhumanCAC
are rare.
In our study, we observe with interest the positive cor-
relation between TNF-𝛼 and NO in plasma of patients with
UC and CAC. Our findings suggest that TNF-𝛼 is involved
in upregulation of NOS2 induction in patients with UC
and CAC. We also evaluated the expression of mRNAs of
TNF-𝛼, TNFR (p55, p75), and NOS2 (iNOS) in colonic
mucosa of patients with UC and CAC. Interestingly, we
have noticed significant levels of mRNA transcripts of
the indicated genes in all groups of patients. In addition,
immunofluorescence analysis showed that TNF-𝛼 and NOS2
expression was also upregulated in colonic mucosa of all
cohorts of patients in comparison with the controls. Our
findings are in agreement with previous data showing the
overexpression of TNF-𝛼 [54] and NOS2 [11] in the inflamed
intestinal mucosa in UC patients, human colon carcinoma
tissue [55], and murine model of carcinoma arising on colitis
[56]. Both TNF-𝛼 and nitric oxide have been suggested
to be an important mediators involved in the initiation
of intestinal inflammation and perpetuation of local tissue
damage [21, 46]. Popivanova et al. showed that TNF-𝛼 is a
crucial mediator of the initiation and progression of colitis
associated colon carcinogenesis [51]. Furthermore, in several
models of chronic inflammation-associated carcinogenesis,
TNFR was predominantly expressed by leukocytes infil-
trating the lamina propria and submucosal regions of the
colon [57]. The TNF-TNFR axis probably contributes to
the development of chronic inflammation-associated colon
carcinogenesis process. The absence of TNFR1 reduced the
infiltration of macrophages and neutrophils, a major source
of COX-2, and eventually depressed colon carcinogenesis
[58]. The excess prostaglandin E2 generated by COX2 in
the recovery period of colitis can induce neovascularization,
aberrant epithelial cell proliferation, and activation of the
Wnt/𝛽-catenin pathway, resulting in the development and
growth of colitis associated neoplasms [59, 60].
Previous works indicated that inducible nitric oxide syn-
thase (iNOS) is expressed by several human gastrointestinal
neoplasms including gastric cancer [61], colonic adenomas
[62], Barrett’s esophagus, and associated adenocarcinomas
[63]. These data suggest that iNOS may play a pivotal role
in the initiation and promotion and probably progression of
cancers arisingwithin a backgroundof inflammation [64, 65].
However, the mechanisms by which inflammation stimulates
the development of cancer remain elusive and are expected to
vary from colitis associated CRC to other forms of CRC [42].
Our results show that histologic examination of biopsies
obtained from CAC patients arising in several ulcerative
colitis reveals a severe mucosal degeneration, crypt loss, and
destruction of epithelium in addition to cellular infiltrates.
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These observations correlate with the high NOS2 and TNF-𝛼
expression in colonic mucosa of the same patients. It can be
argued that NO are clearly implicated in the mucosal injury
observed during CAC pathogenesis.
In our study, we also demonstrate that TLR4 transcript is
highly expressed in inflamed colonic mucosa of UC patients
and CRC patients arising in chronic ulcerative colitis. In
addition, our Western blotting and immunohistochemistry
analysis showed the upregulation of TLR4 in colonic mucosa
of UC and CAC patients. This finding is in agreement with
previous data showing that patients with active UC had
significantlymoreTLR4-positive epithelial cells than controls
[66, 67]. In the same context, several studies reported an
increase in the TLR4 expression in colon cancer cell lines
(HT29, SW480, and KM20) [68, 69]. Fukata et al. showed
that TLR4 is overexpressed in CAC tissue of UC patients
[70]. Furthermore, several preclinical studies showed that
mice deficient in TLR4 are markedly protected against colitis
associated neoplasia [66, 71].
Collectively, these data raise a clear link between TLR4
and CAC development. TLR4 triggers elevated production of
prostaglandin E2, influences epidermal growth factor recep-
tor signaling (EGFR), and increases TNF-𝛼/NOS2 induction
in chronic colitis [71].
LPS has been shown to bind directly to the TLR4/MD2
receptor complex that initiates the intracellular signaling cas-
cade in aMyD88-dependent orMyD88-independentmanner
[72, 73]. LPS-induced TLR4 signaling leads to activation of
various downstream pathways including NF-kB [74]. In our
present study, we evaluated the expression of NF-kB and iKK
in inflamed colonic mucosa fromUC and CAC patients. Our
finding showed that NF-𝜅B and iKK protein expression is
highly increased in colonic mucosa in all groups of patients.
In fact, some studies have shown the overexpression of NF-
𝜅B in the inflamed intestinalmucosa inUC andCACpatients
and murine model of CAC [44, 75].
In our study, the effects of NF-𝜅B activation or inhibition
on TNF𝛼/NOS2 induction are confirmed by ex vivo experi-
ments. Our results showed that SN50 inhibited LPS induction
of NO and TNF-𝛼 production in inflamed colonic mucosa
cultures in all groups of patients. Although SN50 peptide
could also competitively inhibit many transcription factors
such as STAT and AP-1, entering nucleus, it mainly and firstly
inhibits the NF-𝜅B pathway after LPS activation.
The pivotal role of NF-kB signaling in tumor progression
was provided in the AOM-DSS model for colitis associ-
ated colorectal cancer by Greten et al. [76], which showed
that deletion of Ikk in intestinal epithelial cells resulted in
decreased numbers of tumors. In the same way, another
team had also recently demonstrated that TNF-𝛼 inhibition
in the animal model prevents the development of CAC via
blockade of TNF receptor 1 (TNFR1) signaling in infiltrating
hematopoietic cells such as neutrophils and macrophages
[52]. TNF-𝛼 potently induces NF-𝜅B activation but can
also be a NF-𝜅B-target gene [52, 77]. These data suggest
that TLR4/TNF-𝛼 through NF-𝜅B activation could influence
CAC development.
Several hematopoietic and nonhematopoietic lineages
within the gastrointestinal tract, including macrophages,
dendritic cells, and lymphocytes T share the capacity to
synthesize retinoic acid [78, 79]. A number of studies demon-
strated that AtRA has an important modulating role in innate
immunity, with themost recent reports showing that RAhas a
central function in the differentiation of dendritic cells (DCs),
the key APCs for activating naive T cells [80, 81]. Colorectal
tumor cells appear to lose the ability to produce AtRA
[82] while, at the same time, they appear to increase AtRA
degradation via the cytochrome P450 enzyme (CYP26A1), a
major retinoic acid catabolic enzyme [83, 84].
The biological effects of AtRA are mainly mediated by
two families of nuclear retinoic acid receptors (RARs), each
consisting of three receptor subtypes designated by 𝛼, 𝛽, and
𝛾: the RARs and the retinoid X receptors (RXRs) that are
expressed in lymphoid cells and act as transcription factors to
regulate cell signaling, differentiation, and tumor suppression
[85]. In addition to the higher CYP26A1 expression and
the consequential AtRA resistance, as CRC progresses, RAR
𝛽 was downregulated in mice bearing mutations in the
Apc tumor suppressor gene (ApcMIN mouse), human FAP
adenomas, and human sporadic colon carcinomas [86, 87].
The downregulation of RAR 𝛽 may lead to alteration of
cell growth and differentiation in the colon and rectum,
thus contributing to the progression of colorectal cancer.
Several series of preclinical models of colon carcinogenesis
and in vitro system of a retinoid sensitive/resistant human
colon carcinoma cells lines suggested that retinoid mediated
autoinduction of the endogenous RAR 𝛽 gene may play a
crucial role inmediating the biological effects of retinoids [88,
89]. A study of Møllersen et al. using AtRA in the ApcMIN
mouse found enhanced adenoma formation within the small
intestine. In contrast, no changes in adenoma formation were
observed within colon of ApcMIN mice after administration
of AtRA [90]. However, the complexities of retinoic acid
responses in the intestine require further investigation and
greater understanding to propose new therapies, such as
investigating the implication of these factors in the retinoid
synthesis or in their mechanisms of action during inflamma-
tion. In this context, we propose to investigate the efficacy
of AtRA as a new strategy in order to improve the current
therapy in colorectal cancer, including CAC.
In this sense, we aimed to explore the mechanisms
by which AtRA regulates TNF-𝛼 and iNOS expression in
colonic mucosa cultures stimulated with LPS. Our current
studies demonstrated that AtRA decreased TNF and NOS
mRNA expression in inflamed colonic mucosa stimulated
with LPS and also inhibited TNF-𝛼 and NO production
by some colonic mucosa. Our finding suggests that AtRA
modulates LPS-TLR4 signaling targeting TNF-𝛼 and nitric
oxide synthase 2 expression in UC and CAC. These results
are in agreement with previous studies investigating the
inhibitory effect of AtRA on NOS2 expression in human
colon cancer cell lines [91–93].
Several studies reported that AtRA could downregu-
late NOS2 gene expression by direct mechanisms medi-
ated by RARa binding to the putative RARE in the pro-
moter or the NOS2 gene [94]. AtRA could also regulate
directly this expression by a protein-protein interaction with
some transcription factors such as AP-1 [95] and/or NF-kB
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[96, 97], both reported to be involved in the induction of gene
expression of previous inflammatory mediators, including
NOS2 and TNF-𝛼 [52]. In addition, several data suggest
that inhibition of NF-kB translocation to the nucleus may
contribute to the anti-inflammatory mechanisms of AtRA
[98, 99]. Consistent with several findings from other groups
[100–102], our results showed that the immunomodulatory
effects of AtRA on TNF-𝛼 production could be the result
of direct inhibition of cytokine gene expression and could
therefore indirectly decrease NOS2 gene expression.
Overall, our present study strongly supports (i) the pivotal
role of TLR4/NF-𝜅B signaling in UC and CAC pathogenesis
through NO synthase 2 (NOS2) and TNF-𝛼 induction and
(ii) AtRA downregulating NO synthase 2 and TNF-𝛼 expres-
sion targeting the LPS/TLR4/NF-𝜅B pathway. Therefore, we
suggest that AtRA has a potential value in new strategies
to improve the current therapy and probably in the clinical
prevention of CAC development and progression.
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